Sandra Le Quellec, MD, PhD previously served as Assistant Professor of Haematology and had clinical experience managing patients with haemophilia and related bleeding disorders. Her research interests lie in AAV-based gene therapy for haemophilia, and she is currently leading the clinical development program for etranacogene dezaparvovec, the first approved gene therapy for haemophilia B, at CSL Behring.